MARKET

PPBT

PPBT

Purple Biotech Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.820
+0.080
+1.69%
After Hours: 4.820 0 0.00% 17:40 09/21 EDT
OPEN
4.840
PREV CLOSE
4.740
HIGH
4.895
LOW
4.660
VOLUME
110.91K
TURNOVER
--
52 WEEK HIGH
7.25
52 WEEK LOW
3.600
MARKET CAP
84.91M
P/E (TTM)
-0.0990
1D
5D
1M
3M
1Y
5Y
BRIEF-Purple Biotech To Present Overview Of Ongoing Trial Of Multiple Advanced Cancers Treatment
reuters.com · 09/13 12:51
Purple Biotech to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update
One Advanced Pancreatic Cancer Patient Demonstrated a Partial Response in First Dose Cohort in Combination with Nivolumab Patient Enrollment in Second Dose Cohort Complete Study Expanding to Additional Sites in U.S. and Israel REHOVOT, Israel, Sept. 13, 20...
GlobeNewswire · 09/13 11:00
Purple Biotech Provides Corporate Update and Reports First Half 2021 Financial Results
Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today provided a corporate update and ...
GlobeNewswire · 08/05 12:30
60 Biggest Movers From Yesterday
Gainers Ra Medical Systems, Inc. (NYSE: RMED) shares surged 87.3% to close at $9.14 on Monday on abnormally-high session volume.
Benzinga · 06/08 09:17
35 Stocks Moving In Monday's Mid-Day Session
Gainers Ra Medical Systems, Inc. (NYSE: RMED) shares jumped 64.8% to $8.04 on abnormally-high session volume.
Benzinga · 06/07 16:07
Ra Medical Systems, Liminal BioSciences leads healthcare gainers; Cabaletta Bio, MacroGenics among major new losers
Gainers: Ra Medical Systems RMED +54%, Liminal BioSciences LMNL +42%, Atossa Therapeutics (ATOS) +27%, Bionano Genomics BNGO +20%, Clover Health Investments (CLOV) +16%.Losers: Cabaletta Bio (CABA) -10%, MacroGenics (MGNX) -8%, Purple Biotech (PPBT) -8%, I...
Seekingalpha · 06/07 15:02
MoneyGram International, Purple Biotech among premarket losers' pack
Purple Biotech (PPBT) -10%.ShiftPixy (PIXY) -9%.MoneyGram International (MGI) -7% after announces $100M at-the-market equity offering programPanbela Therapeutics (PBLA) -6%.Fuel Tech (FTEK) -6%.BK Technologies (BKTI) -6% after secures $11.1M capital via eq...
Seekingalpha · 06/07 12:11
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 06/07 12:07
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PPBT. Analyze the recent business situations of Purple Biotech Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PPBT stock price target is 25.00 with a high estimate of 25.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 33
Institutional Holdings: 780.02K
% Owned: 4.43%
Shares Outstanding: 17.62M
TypeInstitutionsShares
Increased
3
62.34K
New
4
547.95K
Decreased
3
180.06K
Sold Out
6
247.91K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.40%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/Director
John Waymack
Chief Executive Officer/Director
Itzhak Israel
Chief Financial Officer/Director
Simcha Rock
Vice President - Business Development
Gil Ben-Menachem
General Counsel/Secretary
Avraham Ben-Tzvi
Other
Yisrael Gewirtz
Other
Hadas Reuveni
Independent Director
Ido Agmon
Independent Director
Steven Steinberg
Non-Executive Director
Alain Zeitoun
Independent Director
Philip Serlin
Independent Director
Revital Stern-Raff
Independent Director
Ran Tzror
Independent Director
Arie Weber
No Data
About PPBT
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

Webull offers kinds of Purple Biotech Ltd stock information, including NASDAQ:PPBT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PPBT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PPBT stock methods without spending real money on the virtual paper trading platform.